Literature DB >> 19000993

Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus.

J R Batuca1, P R J Ames, M Amaral, C Favas, D A Isenberg, J Delgado Alves.   

Abstract

OBJECTIVE: To determine whether antibodies against high-density lipoprotein (aHDL) and apolipoprotein A-I (aApo A-I) interfere with the anti-atherogenic functions of high-density lipoprotein (HDL) and relate to disease activity and damage in SLE.
METHODS: Seventy-seven SLE patients were compared with an age- and sex-frequency matched control group. Immunoglobulin G (IgG) aHDL, IgG aApoA-I, soluble vascular cell and intracellular cell adhesion molecules (VCAM-1 and ICAM-1, respectively) were measured by ELISA, paraoxonase (PON) activity by spectrophotometry, nitric oxide (NOx) metabolites by the Griess reaction, and total anti-oxidant capacity (TAC) by chemiluminescence.
RESULTS: Compared with controls, SLE patients showed higher titres of IgG aHDL (P < 0.0001) and IgG aApo A-I (P < 0.0001), lower PON activity (P < 0.0001), increased NOx (P < 0.0001), VCAM-1 (P < 0.0001) and ICAM-1 (P = 0.0008) and lower TAC (P = 0.0006). Titres of IgG aHDL positively correlated with IgG aApo A-I (r = 0.64, P < 0.0001), NOx (r = 0.32, P = 0.007), inversely correlated with PON activity (r = -0.34, P = 0.002) and TAC (r = -0.43, P = 0.0004) and were independently associated with ICAM-1 (t = 3.509, P = 0.001). IgG aApo A-I titres correlated positively with NO (r = 0.37, P = 0.007), inversely with PON activity (r = -0.31, P = 0.006), TAC (r = -0.47, P < 0.0001) and were independently associated with HDL (t = -2.747, P = 0.008) and VCAM-1 (t = 3.311, P = 0.002), the latter alongside NOx (T = 2.271, P = 0.02). Elevated titres of IgG aHDL and IgG aApo A-I and reduced PON activity related to increased disease score (BILAG) and damage index (SLICC/ACR DI).
CONCLUSION: In SLE, IgG aHDL and aApo A-I associate with disease activity and damage and interfere with the anti-oxidant and anti-inflammatory functions of HDL favouring atherogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19000993     DOI: 10.1093/rheumatology/ken397

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  23 in total

1.  Double positivity of the IgG isotype of both anticardiolipin and anti-β2gpI antibodies is associated with the highest number of vascular impairment parameters in patients with primary antiphospholipid syndrome: preliminary data.

Authors:  Mirjana Bećarević; Duško Mirković; Svetlana Ignjatović
Journal:  Clin Rheumatol       Date:  2016-10-14       Impact factor: 2.980

2.  Extended-release niacin increases anti-apolipoprotein A-I antibodies that block the antioxidant effect of high-density lipoprotein-cholesterol: the EXPLORE clinical trial.

Authors:  Joana R Batuca; Marta C Amaral; Catarina Favas; Filipe S Paula; Paul R J Ames; Ana L Papoila; José Delgado Alves
Journal:  Br J Clin Pharmacol       Date:  2017-01-18       Impact factor: 4.335

3.  Anti-apolipoprotein A-1 antibodies and carotid intima-media thickness in Egyptian women with systemic lupus erythematosus.

Authors:  M M Radwan; D El-Lebedy; R Fouda; E Elsorougy
Journal:  Clin Rheumatol       Date:  2014-04       Impact factor: 2.980

4.  Dysfunctional, pro-inflammatory HDL directly upregulates monocyte PDGFRβ, chemotaxis and TNFα production.

Authors:  Brian J Skaggs; Bevra H Hahn; Lori Sahakian; Jennifer Grossman; Maureen McMahon
Journal:  Clin Immunol       Date:  2010-07-15       Impact factor: 3.969

5.  Apolipoprotein a-I at the interface of vascular inflammation and arthritis.

Authors:  Robert Terkeltaub
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-03       Impact factor: 8.311

Review 6.  Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome.

Authors:  Paul R J Ames; Annamaria Margarita; Jose Delgado Alves
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

Review 7.  Effects of inflammation on cholesterol metabolism: impact on systemic lupus erythematosus.

Authors:  Allison B Reiss
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

Review 8.  G2A and LPC: regulatory functions in immunity.

Authors:  Janusz H Kabarowski
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-04-19       Impact factor: 3.072

Review 9.  Autoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunity.

Authors:  Nicolas Vuilleumier; Fabrizio Montecucco; Oliver Hartley
Journal:  World J Cardiol       Date:  2014-05-26

Review 10.  High-Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy.

Authors:  Sang Yeop Kim; Minzhi Yu; Emily E Morin; Jukyung Kang; Mariana J Kaplan; Anna Schwendeman
Journal:  Arthritis Rheumatol       Date:  2019-11-26       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.